Tax Management India. Com
Law and Practice  :  Digital eBook
Research is most exciting & rewarding
  TMI - Tax Management India. Com
Follow us:
  Facebook   Twitter   Linkedin   Telegram

Home Case Index All Cases Income Tax Income Tax + AT Income Tax - 2015 (10) TMI AT This

  • Login
  • Cases Cited
  • Referred In
  • Summary

Forgot password       New User/ Regiser

⇒ Register to get Live Demo



 

2015 (10) TMI 2256 - AT - Income Tax


Issues Involved:
1. Disallowance under section 14A of the Income-tax Act.
2. Disallowance under section 35(2AB) and section 37(1) for R&D expenditure.
3. Disallowance of software expenses under section 37(1) and section 40(a)(ia).

Issue-wise Detailed Analysis:

1. Disallowance under section 14A:

The Revenue's appeal contended that the CIT(A) erred in restricting the disallowance under section 14A to Rs. 1,96,000 without considering the mandatory application of Rule 8D from A.Y. 2008-09 onwards. The Assessee's appeal argued that the disallowance confirmed by the CIT(A) of Rs. 1,65,56,576 was unjustified as it extended to notional expenditure not actually incurred.

Both parties acknowledged that the Tribunal had previously remanded the issue of disallowance under section 14A for A.Y. 2006-07 to the Assessing Officer (AO) for re-adjudication. The Tribunal decided to similarly remand the issue for A.Y. 2007-08 to the AO for a fresh decision, ensuring consistency and avoiding pre-empting the AO's decision for A.Y. 2006-07. Thus, both the Assessee's and Revenue's appeals on this issue were allowed for statistical purposes.

2. Disallowance under section 35(2AB) and section 37(1) for R&D expenditure:

The Assessee contested the disallowance of Rs. 57.66 lakhs out of the claim for deduction under section 35(2AB), which was treated as capital expenditure by the AO. The AO had disallowed the claim on the grounds that the expenditure was not incurred in the 'in-house' research facility but was paid to an external entity, M/s Reliance Clinical Research Services Pvt. Ltd. (RCRS) for clinical trials. The CIT(A) confirmed the disallowance, noting that the amount was capitalized for patent development.

The Assessee withdrew the claim under section 35(2AB) following the Department of Scientific & Industrial Research (DSIR) order, which excluded clinical trial expenses from 'in-house' R&D. However, the Assessee argued for the allowance of these expenses under section 37(1). The Tribunal found the expenses to be genuine and revenue in nature, rejecting the CIT(A)'s view that they were capital expenses. The Tribunal directed the AO to allow the expenses under section 37(1), thus partly allowing the Assessee's appeal on this ground.

3. Disallowance of software expenses under section 37(1) and section 40(a)(ia):

The Assessee claimed software license expenses of Rs. 7,76,132 as revenue expenditure, which the AO disallowed, treating it as capital expenditure and further disallowed under section 40(a)(ia) for non-deduction of TDS. The CIT(A) upheld the disallowance, refusing to admit additional evidence under Rule 46A.

The Tribunal noted that the CIT(A) should have allowed the Assessee to submit evidence under Rule 46A, and thus remanded the issue back to the CIT(A) for re-examination. The Assessee was directed to provide all necessary documents, and the CIT(A) was to reconsider the claim afresh. This ground was allowed for statistical purposes.

Conclusion:

Both the Revenue's and Assessee's appeals were allowed for statistical purposes regarding the disallowance under section 14A. The Assessee's appeal was partly allowed concerning the disallowance under section 35(2AB) and section 37(1), directing the AO to allow the expenses as revenue expenditure. The issue of software expenses was remanded back to the CIT(A) for re-examination, allowing the Assessee to submit further evidence.

 

 

 

 

Quick Updates:Latest Updates